Navigation Links
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Date:11/12/2007

IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), presented today results from the Company's two Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once- daily) formulation, a new formulation of ISTA's ocular, non-steroidal anti- inflammatory agent. The multi-center studies evaluated the new once-daily formulation of Xibrom versus placebo in over 500 patients who underwent cataract surgery. The highly statistically significant findings demonstrated Xibrom QD (once-daily) was superior to placebo (P less than or equal to 0.0001) in achieving both the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery and the secondary efficacy endpoint of elimination of ocular pain at day one. In addition, compared to placebo, bromfenac produced a lower overall incidence of ocular adverse events. William B. Trattler, M.D. presented the results during the 2007 Annual Meeting of the American Academy of Ophthalmology (AAO) being held in New Orleans, Louisiana.

ISTA also announced today a second poster presentation at the AAO meeting. This study demonstrated the currently marketed twice-daily formulation of Xibrom was as effective as both diclofenac sodium 0.1% ophthalmic solution or ketorolac tromethamine 0.5% ophthalmic solution, each dosed four times daily, when used for 3 months in the treatment of cystoid macular edema (CME) following uncomplicated cataract surgery.

Poster Presentations at AAO Meeting:

Monday, November 12th; 12pm - 2pm, Location: Morial Convention Center, Hall D

Abstract # 0259: Integrated Results from 2 Phase III Clinical Trials of a Once Daily Bromfenac Ophthalmic Solution for Ocular S
'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... DUBAI, UAE, February 8, 2012 In the ... diabetic; six countries in the MENA region are among the ... include the United Arab Emirates, Bahrain, Egypt, Kuwait, Oman and ... accounting for 14 percent of its total health care expenditure ...
... 7, 2012  Prometheus Laboratories Inc., a specialty pharmaceutical ... a research and collaboration agreement with an unnamed ... Prometheus, proprietary oncology diagnostic platform (CEER) to develop ... The CEER arrays may ultimately be used in ...
Cached Medicine Technology:Meeting of the Region's Top Diabetes Experts in Dubai this March 2Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company 2
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
(Date:12/26/2014)... The US represents the largest market for ... GlobalData’s forecast estimates that sales of branded therapies were $2.23 ... the high incidence of the disease, high drug treatment rate, ... China. Increased sales of CRC therapies over the forecast period ...
(Date:12/26/2014)... Los Angeles, CA (PRWEB) December 26, 2014 ... score of 3.1 out of 5. This score reflects slightly ... of product specialization, low switching costs and a low level ... low availability of substitutes for cooking and warming equipment and ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... ... , ... ... NEW YORK , March 12 In releasing a new report on maternal health nationwide, Amnesty ...
... ... ... ... NEW YORK , March 12 In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking ...
... 11 Transcendent One, Inc., in conjunction with their wholly-owned IT services subsidiary, TransTech One, is pleased to announce the company,s corporate sponsorship of the 18th Annual ... ... , ... ...
... ... ... Tuesday, March 16, 2010 , ... , , ...
... ... Delivery Systems Identical to the First Product Cannabis Science is Developing for FDA Clinical ... World-Wide , ... Springs, CO (Vocus) March 11, 2010 -- Cannabis Science, Inc. (OTCBB:CBIS), ...
... recent events in the area of the brain called ... long-term memories, as scientists have suspected, than with an ... at Carnegie Mellon University and the University of Minnesota ... maze, the researchers found that replays occurring in the ...
Cached Medicine News:Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 6Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; New Mexico is 49th Among All States in Maternal Mortality 7Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 6Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Arkansas is 44th Among All States in Maternal Mortality 7Health News:Transcendent One, Inc. Sponsors 18th Annual Fresh Start for Kids Celebrity Golf Classic 2Health News:Transcendent One, Inc. Sponsors 18th Annual Fresh Start for Kids Celebrity Golf Classic 3Health News:Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis 2Health News:Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis 3Health News:Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis 4Health News:President Obama's Deputy Drug Czar Tom McClellan Comments in USA TODAY Article 2Health News:President Obama's Deputy Drug Czar Tom McClellan Comments in USA TODAY Article 3Health News:Carnegie Mellon research provides insight into brain's decision-making process 2Health News:Carnegie Mellon research provides insight into brain's decision-making process 3
... of the outstanding features of our Neomax ... Molding Technology. , This manufacturing process allows ... controls the bunching and irritation in the ... wearer. , ,Colors available: Blue, ...
... Flex™ might just be the world's most ... functional support, post-op/rehab support, or both, Flex ... new Accutrac™ ROM hinges control flexion and ... long-term durability while being heat-moldable to accommodate ...
... Donut is a neoprene alternative, constructed ... polyester Lycra Fabric that allows for ... provides for patellar control. Ideal for ... or irritations. Click here to view ...
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: